Spero Therapeutics Inc (SPRO)
1.25
-0.06
(-4.58%)
USD |
NASDAQ |
Nov 14, 16:00
1.28
+0.03
(+2.40%)
Pre-Market: 08:34
Spero Therapeutics Research and Development Expense (Quarterly): 23.72M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 23.72M |
| March 31, 2024 | 17.33M |
| December 31, 2023 | 16.56M |
| September 30, 2023 | 16.39M |
| June 30, 2023 | 9.51M |
| March 31, 2023 | 8.979M |
| December 31, 2022 | 15.09M |
| September 30, 2022 | 7.36M |
| June 30, 2022 | 8.173M |
| March 31, 2022 | 16.97M |
| December 31, 2021 | 17.22M |
| September 30, 2021 | 14.44M |
| June 30, 2021 | 14.46M |
| March 31, 2021 | 18.40M |
| December 31, 2020 | 13.20M |
| September 30, 2020 | 17.71M |
| Date | Value |
|---|---|
| June 30, 2020 | 15.66M |
| March 31, 2020 | 20.44M |
| December 31, 2019 | 25.73M |
| September 30, 2019 | 18.50M |
| June 30, 2019 | 12.03M |
| March 31, 2019 | 9.526M |
| December 31, 2018 | 9.127M |
| September 30, 2018 | 8.459M |
| June 30, 2018 | 7.374M |
| March 31, 2018 | 8.925M |
| December 31, 2017 | 12.50M |
| September 30, 2017 | 6.91M |
| June 30, 2017 | 7.457M |
| March 31, 2017 | 5.999M |
| December 31, 2016 | 6.927M |
| September 30, 2016 | 6.005M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.36M
Minimum
Sep 2022
25.73M
Maximum
Dec 2019
15.65M
Average
16.39M
Median
Sep 2023
Research and Development Expense (Quarterly) Benchmarks
| Arbutus Biopharma Corp | 14.27M |
| Equillium Inc | 10.81M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 4.672M |
| iBio Inc | 1.14M |